No Data
No Data
Appili Therapeutics Q4 Loss Narrows Amid Increase in Government Assistance
Appili Therapeutics (APLI.TO), a biopharmaceutical company focused on drug development for infectious diseases, late on Tuesday said its fiscal fourth-quarter net loss declined by half, mainly because
Appili Therapeutics Announces Additional Bridge Loan From Bloom Burton & Co.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPin
Appili Therapeutics Signs Definitive Agreement to Be Acquired by Aditxt, Inc.
Appili Therapeutics Notes Researchers Publish Manuscript on Prevention and Emergency Response to Tularemia Outbreaks
Appili Therapeutics Inc. (APLI.TO) on Tuesday announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia. Appili's Director of Non-Clinical Research, Dr. Carl Gelh
Appili Therapeutics Brief: Announcing Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Providing Update on Bridge Loan
07:27 AM EST, 12/15/2023 (MT Newswires) -- Appili Therapeutics Brief: Announcing Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Providing Update on Bridg
Appili Therapeutics Brief: As of September 30, 2023, Co Had Cash of $0.4 Million, Compared to $2.5 Million on March 31, 2023.
04:29 PM EST, 11/13/2023 (MT Newswires) -- Appili Therapeutics Brief: As of September 30, 2023, Co had cash of $0.4 million, compared to $2.5 million on March 31, 2023.